SCHEMBL662973

SCHEMBL662973

[CH2]Cc1ccc(CC)cn1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.50
CYP1A2 P05177 1/20 0.49
CYP2D6 P10635 1/20 0.49
KDM4E B2RXH2 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KMT2A Q03164 2/20 0.37
MAPT P10636 1/20 0.37
PPARG P37231 2/20 0.36
CYP3A4 P08684 1/20 0.35
RXRA P19793 1/20 0.35
LMNA P02545 2/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.33
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30398570 0.89 HRH3 (0.55) HRH3CYP1A2CYP2D6KDM4EL3MBTL1
SCHEMBL487617 0.89 HRH3 (0.55) HRH3CYP1A2CYP2D6KDM4EL3MBTL1
SCHEMBL5737703 0.84 HRH3 (0.43) HRH3CYP1A2CYP2D6KDM4EL3MBTL1
SCHEMBL27674580 0.83 HRH3 (0.60) HRH3CYP1A2CYP2D6KDM4EL3MBTL1
SCHEMBL2600004 0.78 HRH3 (0.50) HRH3CYP1A2CYP2D6KDM4EL3MBTL1
SCHEMBL14389059 0.78 HRH3 (0.50) HRH3CYP1A2CYP2D6KDM4EL3MBTL1
SCHEMBL2380517 0.78 HRH3 (0.50) HRH3CYP1A2CYP2D6KDM4EL3MBTL1
SCHEMBL12763633 0.78 HRH3 (0.50) HRH3CYP1A2CYP2D6KDM4EL3MBTL1
SCHEMBL13401237 0.78 HRH3 (0.50) HRH3CYP1A2CYP2D6KDM4EL3MBTL1
SCHEMBL12441410 0.78 HRH3 (0.50) HRH3CYP1A2CYP2D6KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471782-A1 NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME Kowa Company, Ltd. (JP) 2012-07-04 EP disclosed
US-20120122906-A1 NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME KOWA COMPANY, LTD. (JP) 2012-05-17 US disclosed
US-20120046308-A1 NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME KOWA COMPANY, LTD. (JP) 2012-02-23 US disclosed
US-7922317-B2 Ink jet printing apparatus, data generation apparatus and printed product CANON KABUSHIKI KAISHA (JP) 2011-04-12 US disclosed
US-20090216024-A1 Processes for making pioglitazone and compounds of the processes ZHU JIE 2009-08-27 US disclosed
US-7541470-B2 Processes for making pioglitazone and compounds of the processes SYNTHON IP INC. (US) 2009-06-02 US disclosed
EP-1053227-B1 PPAR-GAMMA MODULATORS AMGEN INC (US) 2008-11-05 EP disclosed
US-7439242-B2 PPARγ modulators AMGEN INC. (US) 2008-10-21 US disclosed
US-20070291071-A1 INK JET PRINTING APPARATUS, DATA GENERATION APPARATUS AND PRINTED PRODUCT CANON KABUSHIKI KAISHA (JP) 2007-12-20 US disclosed
US-20070167629-A1 Processes for making pioglitazone and compounds of the processes SYNTHON IP INC. 2007-07-19 US disclosed
US-20050043360-A1 Method for obtaining pioglitazone as an antidiabetic agent LECIVA, A.S. (CZ) 2005-02-24 US disclosed
US-6848781-B2 Image forming process, image-recorded article, liquid composition and ink-jet recording apparatus CANON KABUSHIKI KAISHA (JP) 2005-02-01 US disclosed
US-20040135864-A1 Image forming process, image-recorded article, liquid composition and ink-jet recording apparatus CANON KABUSHIKI KAISHA (JP) 2004-07-15 US disclosed
EP-1403088-A1 Image forming process, image-recorded article, liquid composition and ink-jet recording apparatus CANON KABUSHIKI KAISHA (JP) 2004-03-31 EP disclosed
EP-1387843-A1 METHOD FOR OBTAINING PIOGLITAZONE AS AN ANTIDIABETIC AGENT Leciva, A.S. (CZ) 2004-02-11 EP disclosed
US-6620827-B2 Peroxisome proliferator-activated receptors-gamma to control lipid metabolism ane obesity; antidiabetic, -inflammatory and -arthritic agents; non-insulin dependent diabetes; antilipemic and -cholesterol agents TULARIK INC. 2003-09-16 US disclosed
WO-2002088120-A1 METHOD FOR OBTAINING PIOGLITAZONE AS AN ANTIDIABETIC AGENT Léciva, a.s. (CZ) 2002-11-07 WO disclosed
US-6200995-B1 PYRIDYLOXYBENZENESULFONAMIDE DERIVATIVES; DIABETES, OBESITY TULARIK INC. 2001-03-13 US disclosed
EP-1053227-A1 PPAR-GAMMA MODULATORS TULARIK, INC. (US) 2000-11-22 EP disclosed
WO-1999038845-A1 PPAR-GAMMA MODULATORS TULARIK INC. (US) 1999-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090216024-A1 Processes for making pioglitazone and compounds of the processes PDK4, PDK2, DPP4 HRH3 4492/4885CYP1A2 754/4885CYP2D6 269/4885
US-20120122906-A1 NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME AGTR2, AGTR1, PPARA HRH3 1472/4885CYP1A2 1901/4885CYP2D6 1650/4885
US-20070167629-A1 Processes for making pioglitazone and compounds of the processes PDK4, PDK2, DPP4 HRH3 4492/4885CYP1A2 754/4885CYP2D6 269/4885
US-20120046308-A1 NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME PPARA, PPARG, PPARD HRH3 819/4885CYP1A2 669/4885CYP2D6 419/4885
US-20050043360-A1 Method for obtaining pioglitazone as an antidiabetic agent GLP1R, INSR, CBR3 HRH3 732/4885CYP1A2 1504/4885CYP2D6 969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.